D.E. Shaw & Co’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$945K Buy
559,205
+89,879
+19% +$185K ﹤0.01% 3483
2025
Q4
$929K Buy
+469,326
New +$1.5M ﹤0.01% 3595
2023
Q4
Sell
-16,553
Closed -$275K 4579
2023
Q3
$275K Buy
16,553
+3,417
+26% +$67.7K ﹤0.01% 3648
2023
Q2
$322K Buy
+13,136
New +$316K ﹤0.01% 3577
2022
Q2
Sell
-44,400
Closed -$1.12M 5720
2022
Q1
$1.65M Buy
+44,400
New +$1.88M ﹤0.01% 3495
2021
Q4
Sell
-49,269
Closed -$2.58M 5679
2021
Q3
$3.06M Sell
49,269
-10,721
-18% -$895K ﹤0.01% 2608
2021
Q2
$5.13M Buy
+59,990
New +$3.21M ﹤0.01% 2015
2018
Q4
Sell
-11,778
Closed -$12K 3960
2018
Q3
$12K Sell
11,778
-977
-8% -$1.49K ﹤0.01% 3682
2018
Q2
$26K Sell
12,755
-2,902
-19% -$24.9K ﹤0.01% 3663
2018
Q1
$111K Sell
15,657
-2,300
-13% -$15.5K ﹤0.01% 3384
2017
Q4
$72K Sell
17,957
-600
-3% -$2.42K ﹤0.01% 3516
2017
Q3
$76K Hold
18,557
﹤0.01% 3385
2017
Q2
$76K Sell
18,557
-4,226
-19% -$19.9K ﹤0.01% 3283
2017
Q1
$142K Sell
22,783
-17,159
-43% -$77.9K ﹤0.01% 3168
2016
Q4
$160K Sell
39,942
-7,354
-16% -$34.1K ﹤0.01% 3302
2016
Q3
$331K Sell
47,296
-6,790
-13% -$113K ﹤0.01% 3003
2016
Q2
$829K Sell
54,086
-2,192
-4% -$34.8K ﹤0.01% 2521
2016
Q1
$879K Buy
56,278
+157
+0.3% +$2.03K ﹤0.01% 2436
2015
Q4
$688K Hold
56,121
﹤0.01% 2885
2015
Q3
$719K Sell
56,121
-1,749
-3% -$22.1K ﹤0.01% 2829
2015
Q2
$701K Sell
57,870
-11,372
-16% -$156K ﹤0.01% 2949
2015
Q1
$916K Sell
69,242
-1,518
-2% -$20.5K ﹤0.01% 2636
2014
Q4
$1.01M Buy
70,760
+21,784
+44% +$377K ﹤0.01% 2828
2014
Q3
$1.34M Sell
48,976
-11,839
-19% -$360K ﹤0.01% 2569
2014
Q2
$2.45M Buy
60,815
+11,185
+23% +$414K ﹤0.01% 2146
2014
Q1
$1.91M Buy
49,630
+13,987
+39% +$494K ﹤0.01% 2446
2013
Q4
$1.21M Buy
35,643
+3,520
+11% +$93.5K ﹤0.01% 3000
2013
Q3
$612K Buy
32,123
+1,047
+3% +$18.3K ﹤0.01% 3424
2013
Q2
$481K Buy
+31,076
New +$657K ﹤0.01% 3279

Other funds holding FLNA

D.E. Shaw & Co's FLNA Position: Q1 2026 in Review

D.E. Shaw & Co increased its Filana Therapeutics (FLNA) stake by 19% in Q1 2026, buying an estimated $185K and bringing the position to 559,205 shares worth $945K. The position accounts for ﹤0.01% of the portfolio, ranked #3483.

D.E. Shaw & Co first reported a position in FLNA in Q2 2013 and has held it in 29 quarters since. The position peaked at $5.13M in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • D.E. Shaw & Co held 559,205 shares of Filana Therapeutics worth $945K as of Q1 2026.
  • D.E. Shaw & Co bought 89,879 Filana Therapeutics shares in Q1 2026, an estimated $185K.
  • Filana Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3483 holding.
  • D.E. Shaw & Co first reported a position in Filana Therapeutics in Q2 2013 and has held it in 29 quarters since.
  • D.E. Shaw & Co's Filana Therapeutics position peaked at $5.13M in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.